维布尔混合物治疗高维共变量的脆弱性模型
Fatih Kızılaslan1, David Michael Swanson2, Valeria Vitelli1
1Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Norway.
Statistical methods in medical research
|April 1, 2025
概括
这项研究引入了一种新的韦布尔混合物治疗脆弱性模型,用于审查的生存数据,有效地处理高维的奥米克数据,并确定乳腺癌患者的预后生物标志物.
科学领域:
- 生物统计学 生物统计学
- 计算生物学 计算生物学
- 基因组学就是基因组学.
背景情况:
- 混合治愈模型对于具有治愈分数的生存数据是有价值的,但未得到充分探索,特别是关于脆弱结构和高维数据.
- 现有的方法经常在高维数据集中失败,预测者数量超过观测,限制了它们在像欧米学研究这样的领域的应用.
研究的目的:
- 引入一种新的韦布尔混合物治疗脆弱模型,能够处理受审查的生存数据和高维共变量.
- 开发一个强大的统计框架来分析复杂的生存数据,特别是在高维的奥米克数据集的背景下.
- 使用RNAseq数据识别和验证乳腺癌的预后生物标志物.
主要方法:
- 开发了一种扩展的韦布尔混合治愈模型,其中包含一个脆弱组件,以解释潜在异质性.
- 将高维共变量集成到治愈率和生存组件中,使用适应性弹性网惩罚来进行变量选择.
- 采用一种新的预期最大化 (EM) 算法进行模型推断,并将该方法应用于TCGA RNAseq乳腺癌数据.
主要成果:
- 拟议的混合治愈脆弱性模型在广泛的模拟研究中显示出与现有方法相比,性能优越.
- 从RNAseq数据中确定了一组预后生物标志物,通过功能丰富分析和文献比较进行验证.
- 开发并验证了基于乳腺癌患者确定的生物标志物的预后风险评分指数.
结论:
- 新型混合疗法脆弱性模型为分析高维审查生存数据提供了一种强大而全面的方法,特别是在生物医学研究中.
- 鉴定的生物标志物和风险评分为预测乳腺癌患者的结果提供了宝贵的工具.
- 这种方法推进了统计模型在高维奥米克数据分析中的应用,用于生物标志物发现和预后评估.
相关概念视频
01:14Parametric Survival Analysis: Weibull and Exponential Methods
295
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
295
01:09Truncation in Survival Analysis
135
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
135
01:15Assumptions of Survival Analysis
73
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
73
01:19Expected Frequencies in Goodness-of-Fit Tests
2.5K
A goodness-of-fit test is conducted to determine whether the observed frequency values are statistically similar to the frequencies expected for the dataset. Suppose the expected frequencies for a dataset are equal such as when predicting the frequency of any number appearing when casting a die. In that case, the expected frequency is the ratio of the total number of observations (n) to the number of categories (k).
2.5K
01:21Friedman Two-way Analysis of Variance by Ranks
112
Friedman's Two-Way Analysis of Variance by Ranks is a nonparametric test designed to identify differences across multiple test attempts when traditional assumptions of normality and equal variances do not apply. Unlike conventional ANOVA, which requires normally distributed data with equal variances, Friedman's test is ideal for ordinal or non-normally distributed data, making it particularly useful for analyzing dependent samples, such as matched subjects over time or repeated measures...
112
01:21Cancer Survival Analysis
311
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
311